Orally co-administered drugs

Orally co-administered drugs refers to the clinical practice of administering multiple therapeutic agents via the oral route within the same treatment window. This term does not represent a specific biological target, such as a receptor, enzyme, or ion channel, but instead describes a pharmacological context critical for evaluating drug-drug interactions (StatPearls, 2023, https://www.ncbi.nlm.nih.gov/books/NBK500023/). When drugs are co-administered orally, they may interact during absorption in the gastrointestinal tract, competition for transport proteins like P-glycoprotein, or during first-pass metabolism in the liver (FDA, 2020, https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions). Such interactions can significantly alter the systemic exposure of a drug, potentially leading to therapeutic failure if levels are too low or toxicity if levels are too high (PMC, 2013, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3544442/). Consequently, the study of orally co-administered drugs is a fundamental aspect of clinical pharmacology and regulatory safety assessment (PubMed, 2021, https://pubmed.ncbi.nlm.nih.gov/33073533/).

Other names

Concomitant medicationsCo-medicationsDrug-drug interactionsPolypharmacy

Not applicable; this term refers to a clinical scenario of drug administration rather than a molecular target.